Disease Stratification Through Blood Proteomics and Multivariate Statistics

An important aspect of trauma management involves decisions around the potential secondary sequalae including acute respiratory distress syndrome (ARDS), Acute Kidney disease and coagulopathy. Those decisions in handling treatment would be informed by a capacity to stratify patients according to their trajectory within these secondary co-morbidities.  CytoSage benefits from in-licensed cutting edge proprietary and patent issued proteomic technology from Aeirtec. The assay technology incorporates ultra high assay sensitivity within blood marker multiplexing that avoids loss of data on top of the hierarchy markers that exist in low abundance. CytoSage members have extensive experience in coupling this technology to application of multivariate analysis for interpretation of multiple marker data. Through this route, CytoSage members have previously established marker relationships with immune aspects of ARDS, Stroke and autoimmune disease. Within both autoimmune and dermatological disease they have also established marker profiles of treatment responders and nonresponders (Spencer et al., 2025), but also in the context of the current stratification direction, pretreatment marker profiles providing prediction of therapeutic response.